Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern
In patients with atypical hemolytic uremic syndrome (aHUS), complement blocking by eculizumab rapidly halts the process of thrombotic microangiopathy and it is associated with clear long-term hematologic and renal improvements. Eculizumab treatment consists of a 4-week initial phase with weekly IV a...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Case Reports in Nephrology |
| Online Access: | http://dx.doi.org/10.1155/2016/7471082 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850217365160067072 |
|---|---|
| author | Camino García Monteavaro Carmen Peralta Roselló Borja Quiroga José María Baltar Martín Lorena Castillo Eraso Fernando de Álvaro Moreno Alberto Martínez Vea María Teresa Visus-Fernández de Manzanos |
| author_facet | Camino García Monteavaro Carmen Peralta Roselló Borja Quiroga José María Baltar Martín Lorena Castillo Eraso Fernando de Álvaro Moreno Alberto Martínez Vea María Teresa Visus-Fernández de Manzanos |
| author_sort | Camino García Monteavaro |
| collection | DOAJ |
| description | In patients with atypical hemolytic uremic syndrome (aHUS), complement blocking by eculizumab rapidly halts the process of thrombotic microangiopathy and it is associated with clear long-term hematologic and renal improvements. Eculizumab treatment consists of a 4-week initial phase with weekly IV administration of 900 mg doses, followed by a maintenance phase with a 1,200 mg dose in the fifth week and every 14±2 days thereafter. We present three patients with aHUS and suboptimal response to eculizumab treatment at the usual administration dosage who showed hematologic and renal improvements after an adjustment in the eculizumab treatment protocol. |
| format | Article |
| id | doaj-art-3b2397d942df41aeb1de76a37f08fadf |
| institution | OA Journals |
| issn | 2090-6641 2090-665X |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Nephrology |
| spelling | doaj-art-3b2397d942df41aeb1de76a37f08fadf2025-08-20T02:08:03ZengWileyCase Reports in Nephrology2090-66412090-665X2016-01-01201610.1155/2016/74710827471082Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment PatternCamino García Monteavaro0Carmen Peralta Roselló1Borja Quiroga2José María Baltar Martín3Lorena Castillo Eraso4Fernando de Álvaro Moreno5Alberto Martínez Vea6María Teresa Visus-Fernández de Manzanos7Nephrology Service, Hospital San Agustín, Camino de Heros 6, 33401 Avilés, SpainNephrology Service, Hospital Universitari Joan XXIII, C/Dr. Mallafrè Guasch 4, 43005 Tarragona, SpainNephrology Service, Hospital Universitario de Guadalajara, C/Donante de Sangre s/n, 19002 Guadalajara, SpainNephrology Service, Hospital San Agustín, Camino de Heros 6, 33401 Avilés, SpainNephrology Service, Hospital Universitari Joan XXIII, C/Dr. Mallafrè Guasch 4, 43005 Tarragona, SpainNephrology Service, Hospitales Madrid, Pl. del Conde del Valle de Súchil 16, 28015 Madrid, SpainNephrology Service, Hospital Universitari Joan XXIII, C/Dr. Mallafrè Guasch 4, 43005 Tarragona, SpainNephrology Service, Hospital San Agustín, Camino de Heros 6, 33401 Avilés, SpainIn patients with atypical hemolytic uremic syndrome (aHUS), complement blocking by eculizumab rapidly halts the process of thrombotic microangiopathy and it is associated with clear long-term hematologic and renal improvements. Eculizumab treatment consists of a 4-week initial phase with weekly IV administration of 900 mg doses, followed by a maintenance phase with a 1,200 mg dose in the fifth week and every 14±2 days thereafter. We present three patients with aHUS and suboptimal response to eculizumab treatment at the usual administration dosage who showed hematologic and renal improvements after an adjustment in the eculizumab treatment protocol.http://dx.doi.org/10.1155/2016/7471082 |
| spellingShingle | Camino García Monteavaro Carmen Peralta Roselló Borja Quiroga José María Baltar Martín Lorena Castillo Eraso Fernando de Álvaro Moreno Alberto Martínez Vea María Teresa Visus-Fernández de Manzanos Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern Case Reports in Nephrology |
| title | Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern |
| title_full | Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern |
| title_fullStr | Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern |
| title_full_unstemmed | Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern |
| title_short | Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern |
| title_sort | adjustment of eculizumab dosage pattern in patients with atypical hemolytic uremic syndrome with suboptimal response to standard treatment pattern |
| url | http://dx.doi.org/10.1155/2016/7471082 |
| work_keys_str_mv | AT caminogarciamonteavaro adjustmentofeculizumabdosagepatterninpatientswithatypicalhemolyticuremicsyndromewithsuboptimalresponsetostandardtreatmentpattern AT carmenperaltarosello adjustmentofeculizumabdosagepatterninpatientswithatypicalhemolyticuremicsyndromewithsuboptimalresponsetostandardtreatmentpattern AT borjaquiroga adjustmentofeculizumabdosagepatterninpatientswithatypicalhemolyticuremicsyndromewithsuboptimalresponsetostandardtreatmentpattern AT josemariabaltarmartin adjustmentofeculizumabdosagepatterninpatientswithatypicalhemolyticuremicsyndromewithsuboptimalresponsetostandardtreatmentpattern AT lorenacastilloeraso adjustmentofeculizumabdosagepatterninpatientswithatypicalhemolyticuremicsyndromewithsuboptimalresponsetostandardtreatmentpattern AT fernandodealvaromoreno adjustmentofeculizumabdosagepatterninpatientswithatypicalhemolyticuremicsyndromewithsuboptimalresponsetostandardtreatmentpattern AT albertomartinezvea adjustmentofeculizumabdosagepatterninpatientswithatypicalhemolyticuremicsyndromewithsuboptimalresponsetostandardtreatmentpattern AT mariateresavisusfernandezdemanzanos adjustmentofeculizumabdosagepatterninpatientswithatypicalhemolyticuremicsyndromewithsuboptimalresponsetostandardtreatmentpattern |